Pluri Helping Placenta-Derived Collagen Company Scale Up Production in Europe
Resbiomed, a placental collagen materials manufacturer, is working on scaling up production for what appears regenerative ophthalmology in Europe.
Key findings
- Pluri has finished the first phase of its placenta-derived biomaterials manufacturing program with Resbiomed.
- The work focuses on developing scalable, standardized production of collagen-rich materials from the placenta, potentially for “biosynthetic corneas”.
- The companies are moving into the next phase aimed at process definition, reproducibility, and manufacturing readiness.
A European biomaterial manufacturer, Resbiomed Technologies, has chosen Pluri as its CDMO to manufacture its placenta-derived collagen materials for regenerative medicine, and they’ve reportedly completed the first phase of the project.
It took some investigation to find out what Resbiomed Technologies is and what they’re doing; however, it appears it’s this Bulgarian company, and they mention a focus on ophthalmology, oncology, and endocrinology research.
Their site does not appear to mention biomaterials, but looking at the CEO’s LinkedIn, he posted about the Pluri partnership, stating, “Bio-synthetic cornea becomes a reality in the near future! The ‘Moon shot’…” Here’s a paper on biosynthetic corneas made from synthetic collagen if you’re interested.
He also mentions doing his residency in ophthalmology, so I assume the materials are intended for that, but I cannot confirm.
The project is being run through Pluri’s manufacturing arm, PluriCDMO.
What the collaboration is doing
Pluri says scalable, standardized manufacturing of placenta-derived collagen-rich materials could support use across regenerative medicine, advanced wound care, medical devices, 3D cell culture, bioprinting, and some aesthetics. However, human collagen and collagen-rich materials can be difficult to source and standardize due to quality and input requirements. Research-grade recombinant human collagen is often sold in microgram-to-milligram quantities at premium prices, further complicating manufacturing and sourcing.
To solve this, Pluri Biotech Ltd. (a wholly owned Pluri subsidiary) entered into an agreement with Resbiomed in June 2025. Pluri is applying its placenta-derived processing and bioprocessing capabilities to support Resbiomed in process development intended to enhance, standardize, and enable scalable production of the biomaterials.
This first phase established process development and feasibility; now they’re focused on improving and establishing protocols for tissue extraction, separation, and processing designed to preserve, concentrate, and enhance endogenous collagen components.
The timeline of this next phase was not given, but we look forward to hearing updates this year.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
